Physician profile
Mazen Hakim
NPI 1114016920
$2,483.93
in general payments reported to CMS, 2019-2025
21 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $578 · 2021: $402 · 2022: $280 · 2023: $180 · 2024: $142 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $436.00 | 2019-2023 | |
| Glaxosmithkline, LLC. | $429.43 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $420.49 | 2019-2025 | Airsupra |
| Insmed, INC. | $331.93 | 2020-2025 | Arikayce |
| Genzyme Corporation | $196.49 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.07 | 2019-2021 | |
| Grifols USA, LLC | $66.46 | 2022-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $65.32 | 2019-2022 | |
| Axsome Therapeutics, INC. | $58.36 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $47.47 | 2021-2024 | Dupixent |
| Shire North American Group INC | $42.07 | 2019 | |
| Inspire Medical Systems, INC. | $36.69 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $32.85 | 2022-2023 | Opsumit |
| Sunovion Pharmaceuticals INC. | $32.00 | 2019 | |
| Amgen INC. | $31.40 | 2024 | Tezspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $21.99 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2021 | |
| Inogen, INC. | $17.90 | 2022 | |
| Medtronic, INC. | $16.74 | 2025 | Illumisite |
| Pulmonx Corporation | $16.12 | 2021 | |
| Merck Sharp & Dohme LLC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.